<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="the novel coronavirus disease 2019 (COVID-2019) caused by a laboratory-confirmed" exact="infection" post="of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),"/>
 <result pre="a dire need for new diagnostic and therapeutic modalities. Early" exact="diagnosis" post="is critical in establishing quarantine and limiting the spread"/>
 <result pre="diagnostic and therapeutic modalities. Early diagnosis is critical in establishing" exact="quarantine" post="and limiting the spread of outbreaks; diagnostics later in"/>
 <result pre="fatigue and, less commonly, gastrointestinal manifestations.19 Current biomarkers suggestive of" exact="infection" post="include elevated lactate dehydrogenase, ferritin, D-dimer, erythrocyte sedimentation rate,"/>
 <result pre="the United States, the most widely available diagnostic test is" exact="polymerase chain reaction" post="based, although antibody-based assays are in development and are"/>
 <result pre="mechanisms of infection; and (2) as a platform for high-throughput" exact="screening" post="of potential therapeutics. Currently, it is challenging and clinically"/>
 <result pre="for improved drug candidate screening. The current gold standard for" exact="screening" post="antiviral therapeutics is based on static monolayer culture of"/>
 <result pre="general, the relevance of a drug's ability to inhibit viral" exact="infection" post="of a malignant nonhuman primate (NHP) kidney cell lacking"/>
 <result pre="vitro activity against Ebola in the Vero cell model,26 later" exact="testing" post="in an in vivo NHP model failed to show"/>
 <result pre="the ECM components such as sialic acid to assist in" exact="infection" post="of the host.30 In the last decade, tissue engineering"/>
 <result pre="cultured human epithelial airway cells compared to 2D culture, and" exact="infection" post="with major influenza strains resulted in upregulation of proinflammatory"/>
 <result pre="SARS-CoV-1, which may suggest why normal lung regeneration following viral" exact="infection" post="is challenging.35 There are a number of exciting tissue-engineered"/>
 <result pre="hostâ€&quot;pathogen interface. Scaling these models to allow for high-throughput drug" exact="screening" post="will offer important advantages over the current Vero-based methods"/>
 <result pre="the efficacy of hydroxychloroquine and azithromycin in the prevention and" exact="treatment" post="of SARS-CoV-2 remains an area of active study, the"/>
 <result pre="an exciting class of medication, given their success in the" exact="treatment" post="of Ebola virus.49 Antibodies are a natural part of"/>
 <result pre="damage. Four intranasal doses were required over 5 days in" exact="treatment" post="arms. The researchers reported not using additional vehicles to"/>
 <result pre="SARS-CoV-1 peptide sequence, and subsequent sera was successful in preventing" exact="infection" post="of Vero cells.72 In addition to various particle-based platforms,"/>
 <result pre="a global health-care crisis of unheralded magnitude. The rate of" exact="infection" post="and mortality from COVID-19 make it unlike any virus"/>
 <result pre="for their selfless service on the front lines in the" exact="treatment" post="of patients in this pandemic. Disclosure Statement No competing"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect Dis"/>
 <result pre="cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV)" exact="infection" post="in vitro. Proc Natl Acad Sci U S A103,9530,"/>
 <result pre="BrinkE.N., et al.Human monoclonal antibody as prophylaxis for SARS coronavirus" exact="infection" post="in ferrets. Lancet363,2139, 200415220038 39.LiB.-j., TangQ., ChengD., et al.Using"/>
 <result pre="GuenP., VilleretB., et al.Silver nanoparticle-adjuvanted vaccine protects against lethal influenza" exact="infection" post="through inducing BALT and IgA-mediated mucosal immunity. Biomaterials217,119308, 201931279103"/>
 <result pre="43.GautretP., LagierJ.-C., ParolaP., et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="et al.Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the" exact="treatment" post="of pneumonia. Biomaterials160,107, 201829407340 47.TettS., CutlerD., DayR., and BrownK.Bioavailability"/>
</results>
